Recruiting

Wound Healing

Sponsor:

BioAesthetics

Code:

NCT05484934

Conditions

Post-Mastectomy Breast Deformity (Disorder)

Eligibility Criteria

Sex: Female

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

Regenerative post mastectomy surgery

Study Details

Brief summary:

To evaluate the wound healing response following nipple-areolar complex (NAC) reconstruction with a decellularized donor NAC graft (DCLNAC)

Conditions

Post-Mastectomy Breast Deformity (Disorder)

Study ID

NCT05484934

Start date

Sep 21, 2022

Status verified date

Oct, 2022

Completion date

Oct 7, 2024

Anticipated

Primary completion date

Aug 7, 2024

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18 - 65

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • General Criteria:

  • Females age >18 and <65 years old. Women of childbearing potential must agree to use an acceptable method of contraception for one month prior to DCLNAC implantation, and until the graft is 100% healed. Acceptable forms of birth control include abstinence, birth control pills, or any double combination of: intrauterine device (IUD), male or female condom, diaphragm, sponge, and cervical cap. Nonchildbearing potential for women is defined as postmenopausal (last natural menses greater than 12 months) or undergone a documented bilateral tubal ligation or hysterectomy. If last natural menses less than 12 months, a serum FSH value confirming post-menopausal status can be employed.
  • Patient agrees to sleep on back until study tissue products are healed
  • Patient agrees to abstain from aspirin, alcohol, or excessive caffeine until study tissue products are healed
  • Patient agrees to not undergo NAC tattooing until completing study
  • Patient can understand and willing to sign informed consent
  • Patient desires bilateral nipple reconstruction with DCLNAC
  • Subjects must be capable of providing written informed consent to the study procedures and for use of protected health information \[Health Insurance Portability and Accountability Act (HIPAA), if applicable\]

  • Specific Criteria

Group A:

  • Patient had a bilateral mastectomy with no radiation therapy
  • Patient has undergone a bilateral autologous breast reconstruction a minimum of 3 months prior to enrolling in the study

Group B:

  • Patient had a unilateral mastectomy with no radiation therapy
  • Patient has undergone a unilateral autologous breast reconstruction a minimum of 3 months prior to enrolling in the study

Group C:

  • Patient had a bilateral mastectomy and received radiation unilaterally
  • Patient has undergone a bilateral autologous breast reconstruction a minimum of 3 months prior to enrolling in the study

Group D:

- Patient had unilateral or bilateral mastopexy (with or without augmentation) or reduction mammaplasty and suffered nipple complications (i.e., necrosis, projection loss)

Group E:

  • Patient had unilateral or bilateral mastectomy
  • Patient had unilateral or bilateral autologous breast reconstruction a minimum of 3 months prior to enrolling in the study
  • Patient did not receive radiation to the autologously reconstructed breast
  • Patient had unilateral or bilateral nipple reconstruction that failed (i.e., necrosis, projection loss)

Group F:

- Implant based reconstruction

Exclusion Criteria:

  • Patient has a history of delayed wound healing
  • Patient has a history of Vitamin C deficiency
  • BMI<18.5 or >40 kg/m2
  • Patient has a history of allergic reaction to any decellularized biologic matrix product
  • Patient is currently smoking or using tobacco or nicotine products (i.e., patch, gum, vaping or nasal spray) or has used such products in the past 6 months
  • Patient is currently receiving bilateral breast radiation or completed less than 3 months prior to screening
  • Patient has any systemic disease that would impede wound healing, such as diabetes or connective tissue disorders
  • Patient is pregnant, breastfeeding or planning to become pregnant during the study period
  • Patient has any type of disease or disorder that in the investigator's opinion would make the patient unfit for the study, including active infection anywhere in the body.
  • Acute mastitis in either breast
  • History of an autoimmune disorder
  • Use of any medications currently or in the past 3 months that would impair wound healing, such as long-term use of systemic steroids (inhaled, limited topical, short-term oral use and intra-articular steroids are acceptable)

Study Design

Enrollment

36 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Implant of acellular NAC graft

The implantation of the NAC acellular graft for regenerative nipple areolar complex

Interventions

Regenerative post mastectomy surgery

Implantation of the Nipple-Areolar Complex (NAC) Reconstruction Using a Decellularized Donor NAC Graft (DCLNAC)

Primary outcome measure

  • Time to complete healing (graft >99% re-epithelialized) [ Time Frame: 3 months ]
  • Healing of the nipple (VAS=Visual Analog Scale) epithelialization [ Time Frame: 3 months ]
  • Healing of the nipple (VAS=Visual Analog Scale) granulation [ Time Frame: 3 months ]
  • Healing of the nipple (VAS=Visual Analog Scale) ischemia/necrosis [ Time Frame: 3 months ]
  • Healing of the nipple (VAS=Visual Analog Scale) dehiscence [ Time Frame: 3 months ]
  • Healing of the nipple (VAS=Visual Analog Scale) overall healing [ Time Frame: 3 months ]
  • Healing of the nipple (infection) A. no infection B. hyperemia (no infection) C. cellulitis (superficial infection D. abscess or purulent infection [ Time Frame: 3 months ]

Central Contacts and Locations

Central contacts

Locations

St. Charles Surgical Hospital

Recruiting

New Orleans, Louisiana, United States, 70130

Contacts

More Information

Sponsor

BioAesthetics

Last update posted

Oct 14, 2022

Last verified

Oct, 2022

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by BioAesthetics on 2022-10-14.